Johnson Matthey

The Medicine Maker speaks with Nick Shackley, VP of Johnson Matthey

What are the hottest trends and techniques in drug development?

A good CDMO is a true partner with advice on getting the most from your molecule.

Interest in cannabinoid drug development is growing. The potential market – and the opportunity to treat unmet patient needs – is enormous.

Enzyme engineering has opened up new possibilities in biocatalysis, but computational techniques and smart libraries also make wildtypes feasible. The choice is yours.

Today's small molecules are increasingly complex, but generic producers must keep track of trends

With approximately 80 percent of new drugs suffering from poor solubility and bioavailability, understanding solid form is more important than ever.

Early identification of potential issues within an API’s solid form can accelerate time to market and reduce associated costs.

Our solid state science expertise, under our PHARMORPHIX® brand, supports leading drug discovery and development

JM's API portfolio includes voxelotor, a ground-breaking drug used to treat sickle cell disease.

Crystallisation is a key unit operation in manufacturing APIs, however time and costs pressures have previously limited this.

At JM, we’ve leveraged our knowledge and experience in scientific excellence to develop a novel process to synthesise ultra-pure cannabidiol (CBD)

We work globally with our pharmaceutical customers to deliver expert chemistry solutions for a healthier world.

Biocatalysis is the fastest growing technology for the synthesis of chiral molecules.